MARLBOROUGH, Mass.--(BUSINESS WIRE)--
Hologic, Inc. (Nasdaq: HOLX) announced today that Ludwig N. Hantson has
been elected to the Company’s Board of Directors, effective immediately.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20181119005676/en/
Ludwig N. Hantson Elected to Hologic Board of Directors (Photo: Business Wire)
Dr. Hantson, who has more than 30 years of experience in the life
sciences industry, is the Chief Executive Officer of Alexion
Pharmaceuticals, Inc., a publicly-traded global biopharmaceutical
company. Before joining Alexion, Dr. Hantson was President and Chief
Executive Officer of Baxalta Incorporated. He led Baxalta’s spin-off as
a public company from Baxter in July of 2015. He joined Baxter in May
2010 as the President of Baxter BioScience, and previously held
leadership roles with Novartis AG and Johnson & Johnson.
“It is a pleasure to welcome Ludwig to our Board,” said Steve MacMillan,
Hologic’s Chairman, President and Chief Executive Officer. “With his
experience leading innovative companies, he brings additional depth to
the operational expertise, strategic vision and global perspective of
our Board.”
Dr. Hantson received his Ph.D. in motor rehabilitation and physical
therapy, Master’s degree in physical education, and a certification in
high secondary education, all from the University of Louvain in Belgium.
About Hologic
Hologic, Inc. is an innovative medical technology company primarily
focused on improving women's health and well-being through early
detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic and associated logos are trademarks and/or registered trademarks
of Hologic, Inc. and/or its subsidiaries in the United States and/or
other countries.
Forward-Looking Statements
This news release contains forward-looking information that involves
risks and uncertainties, including statements about the Company's plans,
objectives, expectations and intentions, and statements regarding the
Company's Board of Directors. These forward-looking statements are based
on assumptions made by the Company as of this date and are subject to
known and unknown risks and uncertainties that could cause actual
results to differ materially from those anticipated. These risks
include, but are not limited to, the risk that the Company may not be
able to attract and retain qualified Board members or executives. These
risks are not exhaustive. Other factors that could adversely affect the
Company's business and prospects are described in the filings made by
the Company with the SEC. The Company expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any such
statements presented here to reflect any change in expectations or any
change in events, conditions or circumstances on which any such
statements are based.
SOURCE: Hologic, Inc.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181119005676/en/
Hologic, Inc.
Michael Watts
Vice President, Investor Relations
and Corporate Communications
(858) 410-8588
Source: Hologic, Inc.